Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company specializing in nitric oxide (NO) treatments, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York.
Chairman and CEO Steve Lisi will represent the company, with an on-demand presentation webcast available starting September 5, 2025, at 7:00 a.m. ET. Management will also be available for one-on-one investor meetings during the conference.
Beyond Air (NASDAQ: XAIR), azienda commerciale attiva nei dispositivi medici e nelle biotecnologie specializzata nei trattamenti a base di ossido nitrico (NO), ha annunciato la sua partecipazione al 27° H.C. Wainwright Annual Global Investment Conference, che si terrà dall'8 al 10 settembre 2025 a New York.
Il presidente e CEO Steve Lisi rappresenterà la società; una presentazione on-demand sarà disponibile a partire dal 5 settembre 2025 alle 7:00 ET. La direzione sarà inoltre disponibile per incontri one-to-one con gli investitori durante la conferenza.
Beyond Air (NASDAQ: XAIR), compañía en fase comercial de dispositivos médicos y biofarmacéutica especializada en tratamientos con óxido nítrico (NO), anunció su participación en la 27ª Conferencia Anual Global de Inversión de H.C. Wainwright, que se celebrará del 8 al 10 de septiembre de 2025 en Nueva York.
El presidente y CEO Steve Lisi representará a la empresa; la presentación bajo demanda estará disponible a partir del 5 de septiembre de 2025 a las 7:00 a.m. ET. La dirección también estará disponible para reuniones individuales con inversores durante la conferencia.
Beyond Air (NASDAQ: XAIR), 상업 단계의 의료기기 및 생물의약품 회사로서 일산화질소(NO) 치료법을 전문으로 하는 기업이 H.C. Wainwright 제27회 연례 글로벌 투자 컨퍼런스에 2025년 9월 8일부터 10일까지 뉴욕에서 참가한다고 발표했습니다.
회장을 겸한 CEO 스티브 리시(Steve Lisi)가 회사를 대표하며, 온디맨드 프레젠테이션은 2025년 9월 5일 오전 7:00(ET)부터 시청할 수 있습니다. 경영진은 컨퍼런스 기간 중 투자자와의 일대일 미팅도 진행할 예정입니다.
Beyond Air (NASDAQ: XAIR), société commerciale de dispositifs médicaux et biopharmaceutique spécialisée dans les traitements à l'oxyde nitrique (NO), a annoncé sa participation à la 27e conférence annuelle mondiale sur l'investissement H.C. Wainwright, qui se tiendra du 8 au 10 septembre 2025 à New York.
Le président et CEO Steve Lisi représentera la société ; une présentation à la demande sera disponible à partir du 5 septembre 2025 à 7h00 ET. La direction sera également disponible pour des réunions individuelles avec des investisseurs pendant la conférence.
Beyond Air (NASDAQ: XAIR), ein im kommerziellen Bereich tätiges Medizinprodukte- und Biopharmaunternehmen, das sich auf Stickstoffmonoxid-(NO)-Therapien spezialisiert hat, gab seine Teilnahme an der 27. H.C. Wainwright Annual Global Investment Conference bekannt, die vom 8. bis 10. September 2025 in New York stattfindet.
Vorsitzender und CEO Steve Lisi wird das Unternehmen vertreten; eine On-Demand-Präsentation steht ab dem 5. September 2025 um 7:00 Uhr ET zur Verfügung. Das Management wird während der Konferenz zudem für Einzelgespräche mit Investoren zur Verfügung stehen.
- None.
- None.
GARDEN CITY, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.
An on-demand webcast of the Company’s presentation will be available beginning at 7:00 a.m. ET on Friday, September 5, 2025, on the H.C. Wainwright Conference platform.
In addition, members of management will be available for meetings with investors at the conference. If you are interested in requesting a one-on-one meeting at the conference, please contact your respective representative at H.C. Wainwright to schedule accordingly.
About Beyond Air®, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).
The Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.
About LungFit *
Beyond Air's LungFit is a cylinder-free, phasic flow generator and delivery system designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator-compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders, providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety by eliminating NO2 purging steps, and offering other operational benefits.
LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.
*Beyond Air's LungFit PH is approved for commercial use in the United States, European Union, and many other countries around the world. Beyond Air's other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.
CONTACTS:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
FAQ
When is Beyond Air (XAIR) presenting at the H.C. Wainwright Conference 2025?
Who will represent Beyond Air (XAIR) at the H.C. Wainwright Conference?
How can investors access Beyond Air's (XAIR) presentation at the H.C. Wainwright Conference?
Can investors meet with Beyond Air (XAIR) management at the H.C. Wainwright Conference?
